Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > How is this even possible in this market?

<< Previous

Bullboard Posts

Next >>

Comment by stockman75on Apr 22, 2021 2:43pm

70 Views

Post# 33046410

RE:RE:RE:RE:How is this even possible in this market?

FTV, do you really think confirmation of NASH moves anything? My guess is confirmation of the protocal doesn't even move the needle. I don't think anyone is paying attention to THTX except a very few.

My guess. Only breakthrough cancer news starts to move this old horse....

Hope you are right though!

FredTheVoice wrote: Said it before, and a couple of times in the last weeks....

No confirmation about NASH, no big mouvement around the stock.....

Nothing to do with management.....

FTV.